Navigation Links
Biopure Announces Reverse Stock Split
Date:10/2/2007

CAMBRIDGE, Mass., Oct 2 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) said today that a one-for-five reverse stock split became effective at 12:01 a.m. October 2, 2007, with post-split trading expected to begin when the Nasdaq Capital Market opens today. The outstanding warrants, including those trading on the OTCBB and outstanding options have also been adjusted with the quantities reduced and the exercise prices increased by the 1-for-5 ratio.

At a special stockholder meeting on October 1, 2007, stockholders of the company authorized amending the company's certificate of incorporation to effect a reverse stock split. Pursuant to this authorization, on October 1, 2007 the board approved a one-for-five reverse split of outstanding Biopure class A common stock to take effect on October 2, 2007. The reverse split is intended to broaden Biopure's investor base and help the company gain compliance with the Nasdaq Capital Market's $1.00 minimum bid price listing requirement by increasing the share price.

The company had 77,967,938 shares of class A common stock outstanding at the end of trading on September 28, 2007. The total number of shares outstanding when the market opens on October 2, 2007 will be approximately 15,593,500. The stock is expected to trade for 20 trading days thereafter under the ticker symbol "BPURD" before reverting to "BPUR". Outstanding warrants that trade on the OTCBB will have the following new ticker symbols before reverting to the previous symbols: BPREW reverting to BPURW; BPREZ reverting to BPURZ and BPREL reverting to BPURL.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. Biopure has applied in the United Kingdom for regulatory approval of a proposed orthopedic surgical anemia indication. The company is developing Hemopure for a potential indication in cardiovascular ischemia, in addition to supporting the U.S. Navy's government- funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 bovine)], or HBOC-301, the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 186,000 units of Oxyglobin, which have been used to treat an estimated 100,000 animals.

Statements in this release that are not strictly historical are forward-looking statements, including those statements implying that the reverse stock split may broaden Biopure's investor base or increase the per share price of Biopure Class A common stock. Actual results and their timing may differ materially from those projected in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, unexpected costs and expenses, delays and adverse determinations by regulatory authorities and delays in or unpredictable outcomes of clinical trials, market reaction to the reverse stock split, including the reduction in the number of shares outstanding, and the factors identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q filed on August 14, 2007, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, http://www.sec.gov. The company undertakes no obligation to release publicly the results of any revisions to these forward- looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.

The content of this release does not necessarily reflect the position or the policy of the U.S. Government or the Department of Defense, and no official endorsement should be inferred.

CONTACTS:

Todd Wood

Biopure Corporation

(617) 234-6576

IR@biopure.com

Herb Lanzet (Investors)

H.L. Lanzet Inc.

(212) 888-4570

lanzet@aol.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Beach, CA (PRWEB) , ... January 19, 2017 ... ... Oral Health, is now offering treatments for patients with sleep apnea and TMJ ... consequences for dental and physical health. Dr. Rassouli provides personalized care to reduce ...
(Date:1/19/2017)... PA (PRWEB) , ... January 19, 2017 , ... Allegheny ... experience of patients who seek access to the Network’s programs and services in the ... primary or specialty care appointments will be offered one for that same afternoon. ...
(Date:1/19/2017)... ... January 19, 2017 , ... Tribble Insurance Agency, a family ... Virginia region, is inaugurating a charity event to honor Chad Phillip Dermyer, a local ... last year, Chad Phillip Dermyer and his fellow officers were conducting routine stops of ...
(Date:1/19/2017)... Antonio, TX (PRWEB) , ... January 19, 2017 , ... ... has for the fifth consecutive year donated money to the Triumph Over Kid Cancer ... A. Ragan was one of those children. James saw firsthand the effect of the ...
(Date:1/19/2017)... CA (PRWEB) , ... January 18, 2017 , ... The ... while driving during a rain storm by slowing down and increasing the space between ... Fox 40. Los Angeles based car accident attorney Raymond R. Hassanlou notes that, rain ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... ViewRay, Inc. (Nasdaq: VRAY) announced today that the German Research ... Germany , has purchased a MRIdian Linac ... Heidelberg as part of its initiative for MRI-based radiation ... headed by Medical Director and Professor Jürgen Debus, M.D., ... Cancer Research Center (DKFZ), the Heidelberg Heavy Ion Center ...
(Date:1/19/2017)... New Review of Safinamide ... Symptoms and Motor Complications in Mid- to Late-stage ... ... C Warren Olanow ... 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late Published ...
(Date:1/19/2017)... CLEVELAND , Jan. 18, 2017  ViewRay, ... the world,s first and only clinical MRI-guided radiation ... gross proceeds of approximately $26.1 million through a ... Puissance Capital Management led the financing and was ... OrbiMed Advisors, LLC and Kearny Venture Partners, and ...
Breaking Medicine Technology: